Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Klaus Gaertner is active.

Publication


Featured researches published by Klaus Gaertner.


Biochemical and Biophysical Research Communications | 1987

Inhibition of HIV-associated reverse transcriptase by sugar-modified derivatives of thymidine 5′-triphosphate in comparison to cellular DNA polymerases α and β☆

Eckart Matthes; Ch. Lehmann; Dieter Scholz; M. von Janta-Lipinski; Klaus Gaertner; Hans A. Rosenthal; Peter Langen

Abstract The sugar-modified dTTP analogues 2′,3′-didehydro-2′,3′-dideoxythymidine 5′-triphosphate (ddeTTP), 2′,3′-dideoxythymidine 5′-triphosphate (ddTTP), 3′-fluorothymidine 5′-triphosphate (FdTTP), and 3′-azidothymidine 5′-triphosphate (N3dTTP) are demonstrated to be very effective and selective inhibitors of the HIV-associated reverse transcriptase (HIV-RT). This conclusion is based on a comparison of the IDso values of the compounds for the HIV-RT (ranging from 0.03 μM for ddeTTP to 0.1 μM for ddTTP) and the cellular DNA polymerase α (> 200 μM). DNA polymerase β is partially affected by N3dTTP (IDso=31 μM) and by the other analogues (IDso=1–2.2 μM). FdTTP has proved as effective as N3dTTP (IDso=0.05 μM) in suppressing the HIV-RT activity. Kinetic analysis revealed for both dTTP analogues a competitive type of inhibition and the same K1 values (about 0.05 μM).


Antimicrobial Agents and Chemotherapy | 2007

Strong and Selective Inhibitors of Hepatitis B Virus Replication among Novel N4-Hydroxy- and 5-Methyl-β-l-Deoxycytidine Analogues

Eckart Matthes; Anneko Funk; I. Krahn; Klaus Gaertner; M von Janta-Lipinski; L. Lin; Hans Will; Hüseyin Sirma

ABSTRACT Novel N4-hydroxy- and 5-methyl-modified β-l-deoxycytidine analogues were synthesized and evaluated as anti-hepatitis B virus (HBV) agents. Their in vitro efficiencies were investigated in HepG2.2.15 cells stably transfected with HBV. β-l-2′,3′-Didehydro-2′,3′-dideoxy-N4-hydroxycytidine (β-l-Hyd4C) was most effective in reducing secreted HBV DNA (50% effective concentration [EC50], 0.03 μM), followed by β-l-2′,3′-dideoxy-3′-thia-N4-hydroxycytidine (EC50, 0.51 μM), β-l-2′,3′-dideoxy-N4-hydroxycytidine (EC50, 0.55 μM), and β-l-5-methyl-2′-deoxycytidine (EC50, 0.9 μM). The inhibition of the presumed target, the HBV DNA polymerase, by the triphosphates of some of the β-l-cytidine derivatives was also assessed. In accordance with the cell culture data, β-l-Hyd4C triphosphate was the most active inhibitor, with a 50% inhibitory concentration of 0.21 μM. The cytotoxicities of some of the 4-NHOH-modified β-l-nucleosides were dramatically lower than those of the corresponding cytidine analogues with the unmodified 4-NH2 group. The 50% cytotoxic concentrations for β-l-Hyd4C in HepG2 and HL-60 cells were 2,500 μM and 3,500 μM, respectively. In summary, our results demonstrate that at least β-l-Hyd4C can be recommended as a highly efficient and extremely selective inhibitor of HBV replication for further investigations.


Nucleosides, Nucleotides & Nucleic Acids | 1991

Synthesis and Anti-HIV Activity of Modified 2′,3′-Dideoxy-3′-Fluoro Pyrimidine Nucleosides

M. von Janta-lipinski; Klaus Gaertner; Jürgen Schildt; E. Matther; Dieter Scholz; P. Langon

Abstract - Among the 2′, 3′ -dideoxy-3′-fluoro pyrimidine nucleosidea modified at C-4 and C-5 several congeners have been identified which show a selective inhibition of HIV-1 replication in vitro.


Archive | 1988

Fluorinated nucleosides and process for treating retrovirus infections therewith

Eckart Matthes; Christine Lehmann; Dieter Scholz; Martin von Janta-Lipinski; Klaus Gaertner; Peter Langen; Hans-Alfred Prof. Dr. Rosenthal


Archive | 1987

Fluorinated nucleoside, process for their preparation and their use as a pharmaceutical product against aids

Eckart Matthes; Christine Lehmann; Dieter Scholz; Janta-Lipinski Martin Dr. Von; Klaus Gaertner; Peter Langen; Hans-Alfred Prof. Dr. Rosenthal


Archive | 1987

Fluorinated nucleosides,their preparation and their pharmaceutical use against AIDS

Eckart Matthes; Christine Lehmann; Dieter Dr. Scholz; Janta-Lipinski Martin Dr. Von; Klaus Gaertner; Peter Langen; Hans-Alfred Prof. Dr. Rosenthal


Archive | 1994

2',3'-dideoxynucleoside pyrimidine compounds and carbocyclic analogs

Eckart Matthes; Martin von Janta-Lipinski; Dieter Scholz; Klaus Gaertner; Juergen Schildt; Christine Lehmann; Peter Langen; Hans A. Rosenthal


Archive | 1989

Substituted pyrimidine nucleosides, process for their preparation and pharmaceutical compounds containing them

Eckart Matthes; Janta-Lipinski Martin Dr. Von; Dieter Scholz; Klaus Gaertner; Jürgen Schildt; Christine Lehmann; Peter Langen; Hans-Alfred Prof. Dr. Rosenthal


Zeitschrift für Chemie | 2010

Nucleoside von Fluor‐Zuckern; Synthese neuer potentieller DNS‐Hemmstoffe

Gotthard Kowollik; Klaus Gaertner; Peter Langen


Zeitschrift für Chemie | 2010

Zur regiospezifischen Substitution an 6-Fluor-thyminnucleosiden

Martin von Janta-Lipinski; Klaus Gaertner; Peter Langen; Erhard Mittag

Collaboration


Dive into the Klaus Gaertner's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Dieter Scholz

Humboldt University of Berlin

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jürgen Schildt

Max Delbrück Center for Molecular Medicine

View shared research outputs
Top Co-Authors

Avatar

Hans A. Rosenthal

Humboldt University of Berlin

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge